Novo Nordisk A/S (NONOF)
| Previous close | 122.81 |
| Open | 122.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 122.00 - 124.95 |
| 52-week range | 74.70 - 140.32 |
| Volume | |
| Avg. volume | 41,951 |
| Market cap | 553.362B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 46.59 |
| EPS (TTM) | 2.65 |
| Earnings date | N/A |
| Forward dividend & yield | 1.86 (1.51%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | N/A |
Investor's Business DailyHow The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.
- Reuters
India's Biocon developing its own version of Wegovy, clinical trial likely next year
Indian drugmaker Biocon , looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.
Investor's Business DailyIs Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?
Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?
